<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42445">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02553772</url>
  </required_header>
  <id_info>
    <org_study_id>11182X-001</org_study_id>
    <nct_id>NCT02553772</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of a new eye drop formulation in patients
      with dry eye disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Ocular Surface Disease Index© (OSDI©) Score on a 5-Point Scale</measure>
    <time_frame>Baseline, Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Tear Break-up Time (TBUT)</measure>
    <time_frame>Baseline, Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Corneal Staining on a 6-Point Scale</measure>
    <time_frame>Baseline, Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Conjunctival Staining on a 6-Point Scale</measure>
    <time_frame>Baseline, Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Schirmer Test</measure>
    <time_frame>Baseline, Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Carboxymethylcellulose Based Eye Drop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboxymethylcellulose based eye drop administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REFRESH OPTIVE® ADVANCED</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboxymethylcellulose Based Eye Drop</intervention_name>
    <description>Carboxymethylcellulose based eye drop administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.</description>
    <arm_group_label>Carboxymethylcellulose Based Eye Drop</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboxymethylcellulose Sodium 0.5%</intervention_name>
    <description>Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.</description>
    <arm_group_label>REFRESH OPTIVE® ADVANCED</arm_group_label>
    <other_name>REFRESH OPTIVE® ADVANCED</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Used artificial tears for dry eye

          -  Visual acuity of at least 20/32 (while wearing glasses, if necessary).

        Exclusion Criteria:

          -  Use of contact lenses in the last 3 months, or anticipated use of contact lenses
             during the study

          -  Herpes keratitis in the last 6 months

          -  Cataract surgery, laser-assisted in situ keratomileusis [LASIK], or photorefractive
             keratectomy, within the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Private Practice of Milton Hom, OD</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Havana Research Institute LLC</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lugene Eye Institute</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eric M. White, OD, INC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moyes Eye Center, PC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Ophthalmological Group, PC</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye Ear Nose</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and Christie and Associate</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texan Eye</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Optometry &amp; Vision Sciences, The University of Melbourne</name>
      <address>
        <city>Parkville</city>
        <zip>VIC 3010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. M.T. Coroneo Pty. Ltd.</name>
      <address>
        <city>Randwick</city>
        <zip>NSW 2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of New South Wales School of Optometry and Vision Science</name>
      <address>
        <city>Sydney</city>
        <zip>NSW 2052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com</url>
    <description>More Information</description>
  </link>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 4, 2016</lastchanged_date>
  <firstreceived_date>September 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
